United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.
United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler. The company also markets Unituxin (dinutuximab) for certain pediatric patients with high-risk neuroblastoma. Its products are sold in the United States and select international markets, subject to regulatory approvals.
Founded in 1996 by Martine Rothblatt, United Therapeutics is headquartered in Silver Spring, Maryland. In addition to its pharmaceutical business, the company is pursuing technologies intended to address the shortage of transplantable organs, including organs from genetically modified animals and bioengineered or manufactured lungs. These efforts are conducted through subsidiaries and affiliated operations such as Lung Biotechnology and Revivicor.
Martine Rothblatt serves as United Therapeutics’ chairperson and chief executive officer. The company’s research and development activities span pulmonary medicine, organ transplantation, xenotransplantation and regenerative medicine, supporting its broader mission of extending and improving human life.
AI Generated. May Contain Errors.
Free UTHR Stock Alerts